Literature DB >> 23417672

Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.

Justin D Walter1, Rachel A Werther, Maria S Polozova, Julie Pohlman, John F Healey, Shannon L Meeks, Pete Lollar, P Clint Spiegel.   

Abstract

The most significant complication for patients with severe cases of congenital or acquired hemophilia A is the development of inhibitor antibodies against coagulation factor VIII (fVIII). The C2 domain of fVIII is a significant antigenic target of anti-fVIII antibodies. Here, we have utilized small angle x-ray scattering (SAXS) and biochemical techniques to characterize interactions between two different classes of anti-C2 domain inhibitor antibodies and the isolated C2 domain. Multiple assays indicated that antibodies 3E6 and G99 bind independently to the fVIII C2 domain and can form a stable ternary complex. SAXS-derived numerical estimates of dimensional parameters for all studied complexes agree with the proportions of the constituent proteins. Ab initio modeling of the SAXS data results in a long kinked structure of the ternary complex, showing an angle centered at the C2 domain of ∼130°. Guided by biochemical data, rigid body modeling of subunits into the molecular envelope of the ternary complex suggests that antibody 3E6 recognizes a C2 domain epitope consisting of the Arg(2209)-Ser(2216) and Leu(2178)-Asp(2187) loops. In contrast, antibody G99 recognizes the C2 domain primarily through the Pro(2221)-Trp(2229) loop. These two epitopes are on opposing sides of the fVIII C2 domain, are consistent with the solvent accessibility in the context of the entire fVIII molecule, and provide further structural detail regarding the pathogenic immune response to fVIII.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417672      PMCID: PMC3617290          DOI: 10.1074/jbc.M112.424564

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

1.  Determination of domain structure of proteins from X-ray solution scattering.

Authors:  D I Svergun; M V Petoukhov; M H Koch
Journal:  Biophys J       Date:  2001-06       Impact factor: 4.033

2.  Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689.

Authors:  K Nogami; M Shima; K Hosokawa; M Nagata; T Koide; E L Saenko; I Tanaka; M Shibata; A Yoshioka
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

3.  Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.

Authors:  E P Mauser-Bunschoten; J G van der Bom; M Bongers; M Twijnstra; G Roosendaal; K Fischer; H M van den Berg
Journal:  Haemophilia       Date:  2001-07       Impact factor: 4.287

Review 4.  The future of plasma-derived clotting factor concentrates.

Authors:  W K Hoots
Journal:  Haemophilia       Date:  2001-01       Impact factor: 4.287

5.  Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

Authors:  P C Spiegel; M Jacquemin; J M Saint-Remy; B L Stoddard; K P Pratt
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

6.  Structure of the C2 domain of human factor VIII at 1.5 A resolution.

Authors:  K P Pratt; B W Shen; K Takeshima; E W Davie; K Fujikawa; B L Stoddard
Journal:  Nature       Date:  1999-11-25       Impact factor: 49.962

Review 7.  Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.

Authors:  I Scharrer; G L Bray; O Neutzling
Journal:  Haemophilia       Date:  1999-05       Impact factor: 4.287

8.  Role of factor VIII C2 domain in factor VIII binding to factor Xa.

Authors:  K Nogami; M Shima; K Hosokawa; T Suzuki; T Koide; E L Saenko; D Scandella; M Shibata; S Kamisue; I Tanaka; A Yoshioka
Journal:  J Biol Chem       Date:  1999-10-22       Impact factor: 5.157

9.  Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products.

Authors:  Wolfhart Kreuz; Carmen Escuriola Ettingshausen; Alex Zyschka; Johannes Oldenburg; Inmaculada Martinez Saguer; Silke Ehrenforth; Thomas Klingebiel
Journal:  Semin Thromb Hemost       Date:  2002-06       Impact factor: 4.180

10.  The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

Authors:  J M Lusher; C A Lee; C M Kessler; C L Bedrosian
Journal:  Haemophilia       Date:  2003-01       Impact factor: 4.287

View more
  10 in total

1.  Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Authors:  P M Zakas; K Vanijcharoenkarn; R C Markovitz; S L Meeks; C B Doering
Journal:  J Thromb Haemost       Date:  2014-11-11       Impact factor: 5.824

2.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Authors:  A M Sevy; J F Healey; W Deng; P C Spiegel; S L Meeks; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

3.  High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance.

Authors:  Phuong-Cac T Nguyen; Kenneth B Lewis; Ruth A Ettinger; Jason T Schuman; Jasper C Lin; John F Healey; Shannon L Meeks; Pete Lollar; Kathleen P Pratt
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113

Review 4.  Engineering less immunogenic and antigenic FVIII proteins.

Authors:  Kathleen P Pratt
Journal:  Cell Immunol       Date:  2015-11-02       Impact factor: 4.868

5.  Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes.

Authors:  Justin D Walter; Rachel A Werther; Caileen M Brison; Rebecca K Cragerud; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  Blood       Date:  2013-10-01       Impact factor: 22.113

6.  Six amino acid residues in a 1200 Å2 interface mediate binding of factor VIII to an IgG4κ inhibitory antibody.

Authors:  Jasper C Lin; Ruth A Ettinger; Jason T Schuman; Ai-Hong Zhang; Muhammad Wamiq-Adhami; Phuong-Cac T Nguyen; Shelley M Nakaya-Fletcher; Komal Puranik; Arthur R Thompson; Kathleen P Pratt
Journal:  PLoS One       Date:  2015-01-23       Impact factor: 3.240

7.  The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces.

Authors:  Caileen M Brison; Steven M Mullen; Michelle E Wuerth; Kira Podolsky; Matthew Cook; Jacob A Herman; Justin D Walter; Shannon L Meeks; P Clint Spiegel
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

8.  A New in Silico Antibody Similarity Measure Both Identifies Large Sets of Epitope Binders with Distinct CDRs and Accurately Predicts Off-Target Reactivity.

Authors:  Astrid Musnier; Thomas Bourquard; Amandine Vallet; Laetitia Mathias; Gilles Bruneau; Mohammed Akli Ayoub; Ophélie Travert; Yannick Corde; Nathalie Gallay; Thomas Boulo; Sandra Cortes; Hervé Watier; Pascale Crépieux; Eric Reiter; Anne Poupon
Journal:  Int J Mol Sci       Date:  2022-08-28       Impact factor: 6.208

9.  Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody.

Authors:  Michelle E Wuerth; Rebecca K Cragerud; P Clint Spiegel
Journal:  Sci Rep       Date:  2015-11-24       Impact factor: 4.379

10.  Structure of Blood Coagulation Factor VIII in Complex With an Anti-C2 Domain Non-Classical, Pathogenic Antibody Inhibitor.

Authors:  Estelle K Ronayne; Shaun C Peters; Joseph S Gish; Celena Wilson; H Trent Spencer; Christopher B Doering; Pete Lollar; P Clint Spiegel; Kenneth C Childers
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.